+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Genetic variations in VEGF and VEGFR2 and glioblastoma outcome

Genetic variations in VEGF and VEGFR2 and glioblastoma outcome

Journal of Neuro-Oncology 104(2): 523-527

Vascular endothelial growth factor (VEGF) and its receptors (VEGFR) are central components in the development and progression of glioblastoma. To investigate if genetic variation in VEGF and VEGFR2 is associated with glioblastoma prognosis, we examined blood samples from 154 glioblastoma cases collected in Sweden and Denmark between 2000 and 2004. Seventeen tagging single nucleotide polymorphisms (SNPs) in VEGF and 27 in VEGFR2 were genotyped and analysed, covering 90% of the genetic variability within the genes. In VEGF, we found no SNPs associated with survival. In VEGFR2, we found two SNPs significantly associated to survival, namely rs2071559 and rs12502008. However, these results are likely to be false positives due to multiple testing and could not be confirmed in a separate dataset. Overall, this study provides little evidence that VEGF and VEGFR2 polymorphisms are important for glioblastoma survival.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 053389568

Download citation: RISBibTeXText

PMID: 21191630

DOI: 10.1007/s11060-010-0504-2

Related references

Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling. Cancer Letters 382(1): 44-52, 2016

VEGF-C Sustains VEGFR2 Activation under Bevacizumab Therapy and Promotes Glioblastoma Maintenance. Neuro-Oncology, 2018

Correlation of VEGF and VEGFR2 expression with anti-tumor efficacy of VEGFR2 tyrosine kinase inhibitors and an anti-VEGF monoclonal antibody in xenografts. Proceedings of the American Association for Cancer Research Annual Meeting 44: 933, July, 2003

Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle 7(16): 2553-2561, 2008

Genetic variations in EGF and EGFR and glioblastoma outcome. Neuro-Oncology 12(8): 815-821, 2010

VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling. Circulation Research 103(9): 916-918, 2008

Anti-VEGFR2 driven nuclear translocation of VEGFR2 and acquired malignant hallmarks are mutation dependent in glioblastoma. Journal of Cancer Science & Therapy 8(7): 172-178, 2017

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models. British Journal of Cancer 91(7): 1391-1398, 2004

Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Annals of Oncology 21(6): 1179-1188, 2010

VEGF, VEGF isoforms and VEGFR2 in human skeletal muscle. FASEB Journal 17(4-5): Abstract No 320 8, March, 2003

Isolation and characterization of neutralizing human anti-VEGF scFv antibody that specifically blocks VEGF from binding to VEGFR2. Proceedings of the American Association for Cancer Research Annual Meeting 44: 1292, July, 2003

Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Breast Cancer Research and Treatment 89(2): 135-143, 2005

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 118(7): 1946-1954, 2012

VEGF isoforms as outcome biomarker for anti-angiogenic therapy in recurrent glioblastoma. Neurology 84(18): 1906-1908, 2015

VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation. Molecular Biology of the Cell 22(15): 2766-2776, 2011